GUIDELINES

Guidelines to PET measurements of the target occupancy in the brain for drug development

Akihiro Takano1 · Andrea Varrone1 · Balázs Gulyás1 · Piero Salvadori2 · Antony Gee3 · Albert Windhorst4 · Johnny Vercouillie5 · Guy Bormans6 · Adriaan A. Lammertsma4 · Christer Halldin1

Received: 22 July 2016 / Accepted: 25 July 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract This guideline summarizes the current view of the European Association of Nuclear Medicine Drug Development Committee. The purpose of this guideline is to guarantee a high standard of PET studies that are aimed at measuring target occupancy in the brain within the framework of development programs of drugs that act within the central nervous system (CNS drugs). This guideline is intended to present information specifically adapted to European practice. The information provided should be applied within the context of local conditions and regulations.

Keywords Drug development · Target occupancy · Positron emission tomography

Background

Positron emission tomography (PET) is a molecular imaging tool well suited for in vivo imaging and quantifying receptors, transporters, and enzymes in the brain that can be potential targets for CNS drugs. Within drug development programs at the industrial level, the average cost for a drug to be brought to the market is approximately US$ 1 billion, and the time needed for the process is typically up to 15 years [1]. In addition, based on estimates of the US Food and Drug Administration (FDA), there is less than a 10 % chance for a drug entering clinical trials to reach the market, often because of lack of efficacy, undesirable side-effects, or inappropriate kinetics [2]. In the CNS, despite the presence of several hundreds of potential targets for new drugs, the functional relevance of most of the proteins in the human brain is not fully understood, especially in relation to the doses of new drugs. Inappropriate selection of doses, namely too high or too low doses, may lead to failure of the drug development in phases 2 and/or 3. Measurement of target occupancy in the brain in vivo is expected to be useful for an appropriate dose setting.

These guidelines are primarily focused on the use of positron emission tomography as a molecular imaging tool to investigate the fraction of the total target population (receptor, transporter or enzyme, etc.) in the brain that is occupied by a CNS drug [3].

In these guidelines, we assume that standard stand-alone PET systems and appropriate PET reconstruction algorithms are implemented and used for the PET occupancy study. Regular calibration of the PET systems should be performed to validate the data acquisition. When PET/CT or PET/MRI is considered for use, extra cautions for each modality’s characteristics such as radiation from CT and issues of the attenuation and scatter corrections related to MRI should be taken into consideration. The bias introduced by different PET
reconstruction algorithms should be also considered before the study starts. The issues related to validation of the modal-
ties should be checked elsewhere.

We hope that these guidelines would help all researchers who are interested in the target occupancy study of CNS
drugs, especially to researchers who aim to establish and/or improve the collaborative PET studies for drug development
between academic sites and pharmaceutical companies.

All preclinical and clinical PET occupancy studies should have ethical approvals from relevant committees before the
studies start. Clinical studies should follow the declaration of Helsinki and possibly organize the central recordings of the
PET studies.

**Key issues to consider for the PET occupancy study**

**Selection of appropriate radioligands**

The following three criteria are recommended for radioligands used in PET occupancy studies.

1. High specific binding and selectivity for the target
   If the ratio of specific to nonspecific binding is low, the outcome measures will be less robust. If a radioligand
   binds to several targets (i.e., has low selectivity), the occupancy calculated for the test drug may be
   underestimated, if the latter is selective for a single target. If test drug and radioligand both bind competitively to off-
target sites, the occupancy might be calculated incorrectly. If possible, information on in vitro affinities for both target
   and off-target sites should be obtained prior to PET occupancy studies.

2. Well-established quantitative methods for measuring radioligand binding
   Quantitative methods for measuring radioligand binding should be established well before PET occupancy
   studies. To calculate occupancy, outcome measures of these methods should preferably reflect specific binding
to the target (e.g., binding potential (BP$_{ND}$) or specific distribution volume ($V_S$)) [4]. Reversibility and level of
   non-displaceable binding of the tracer, together with total length and framing of the dynamic PET measurement
   should be established in advance. Radioligands for which BP$_{ND}$ or $V_S$ are difficult to estimate are discussed later in
   section E.

3. Low test-retest variability of outcome measures of the radioligand
   Although there is no definite threshold for the test-retest variability needed for occupancy studies, clearly variability
   should be as low as possible. When test-retest variability is high, more data points are needed for robust characteriza-
tion of the dose-occupancy curve. Apart from the radioligand itself, test-retest variability depends on several
other factors such as the PET facilities and auxiliary equipment used. In any case, test-retest variability should be
measured prior to or as part of the occupancy study.

**Selection of subjects**

**Experimental animals (nonhuman primates, pigs, rats, etc.)**

If experimental animals are available at the local PET facility, preclinical PET occupancy studies can be considered before studies in human subjects. Preclinical PET studies should only be performed in a complimentary and/or bridging manner to the clinical PET occupancy study, i.e., when full occupancy cannot be achieved in humans because of safety reasons. It should be considered that there may be species differences in the kinetic behaviour and metabolism of the radioligand and the test drug. Therefore, preclinical studies should be designed in such a way that they are relevant for the human situation. The choice of experimental animals is essential in ensuring that results of occupancy studies can be translated to human subjects. Although the accessibility to the nonhuman primates (NHP) is limited in some parts of Europe, non-human primates are typically considered as a suitable model to predict the behaviour of a drug and a PET radioligand in the human brain.

**Human subjects (healthy volunteers, patients), gender and age**

In general, healthy volunteers are appropriate for human PET occupancy studies, at least in the initial stages of developing a
new drug. If the target density is expected to be variable during the menstrual cycle or when other gender factors could
play a role, inclusion/exclusion criteria or the schedule of PET measurements should be adjusted accordingly. Inclusion/ exclusion criteria of healthy volunteers should be defined for each PET occupancy study, considering possible confounding variables for each target.

Certain drug targets in the brain, e.g., dopamine receptors are known to decrease with age. Nevertheless, as it can be considered to be stable during the short time interval of a PET occupancy study, i.e., within 1–2 months, age effects on occupancy measurements usually are negligible (for repeat measurements in the same healthy subjects).

Clearly, if a test drug is intended for a certain age range and/or gender, e.g., test drugs for dementia, and pharmacokinetic
parameters are expected to depend on age and/or gender, occupancy studies should be performed in the appropriate target
population. In addition, when patients are included in an occupancy study, it is always important to verify whether previous
chronic drug treatment has had any effects on the binding of the
radioligand to the target (e.g., because of very slow dissociation from the target or by altering expression of the target).

**Designing and scheduling of the study**

**Preclinical PET occupancy study**

At least one baseline PET measurement (i.e., when no test drug is administered before PET measurement) and one pretreatment PET measurement (i.e., the test drug is administered before PET measurement) should be performed for each experimental animal. During PET measurements, vital signs, such as blood pressure, heart rate, ECG, and blood oxygenation should be monitored to evaluate potential side effects. In principle, even when a preclinical PET occupancy study is performed in the early phase of drug development, ideally safety data of the test drug should be available prior to the PET study, especially in the case of NHP. Although a wide range of doses for the test drug are investigated in a PET occupancy study, the highest dose should be lower than the maximal safe dose. An example PET schedule using NHP, in which four occupancy data points are obtained in 2 days, is shown in Fig. 1.

The study design and scheduling of the preclinical PET occupancy study depends on the following factors:

a. Radioligand synthesis at the facility
   - How many times per day can the radioligand be synthesized?

b. Availability of experimental animals
   - What is the maximum allowable time per experiment?
   - What is the maximum allowable number of measurements per experimental animal?
   - Are studies without anaesthesia possible?
   - Type of anaesthesia, its interaction with radioligand and/or test drug. Preferably in vitro data about the effects on the radioligand binding by anaesthesia should be available prior to PET occupancy study.

c. Characteristics of the radioligands
   - The half-life of the radionuclide (e.g., C-11 or F-18) used for labelling, defining the minimum interval between measurements (at least 5 half-lives).
   - Brain kinetics of the radioligand, defining minimum duration of a PET measurement, e.g., 60 min for [11C]raclopride (dopamine D2 receptor), and requiring a radionuclide with a suitable half-life.

d. Blood sampling and metabolite analysis
   - For many PET radioligands (i.e., all radioligands without a valid reference region), measurement of the arterial input function is necessary for

---

**Fig. 1** Example of a schedule of a PET occupancy protocol using a C-11 labelled ligand. Two nonhuman primates are enrolled in the study. A total of three PET measurements, one baseline measurement followed by two pretreatment (one at low and one at higher dose) measurements, are performed in each nonhuman primate on the same day. In the second nonhuman primate, the drug dose can be adjusted based on the results of the first (adaptive design). According to this schedule, four occupancy data points can be obtained in 2 days.

If the radioligand is labelled with F-18, only one PET measurement can be performed per day due to the longer half-life and more days are required to obtain the same four occupancy data points.
quantitative analysis of occupancy studies, raising the following issues:

Is arterial sampling feasible?
What is the maximum allowable blood volume that can be withdrawn (e.g., in repeat measurements)?
Is equipment for metabolite analysis and measurement of protein binding available?

Pharmacokinetics of the test drug

- Routes of drug administration, i.e., orally, intravenous or intramuscular?
- In case of intravenous administration, bolus, bolus plus constant infusion, slow infusion, or acute vs chronic dosing?
- Time to reach maximal plasma level of the drug ($T_{\text{max}}$) and time at the trough level of the drug ($T_{\text{trough}}$).
- Presence of active metabolites?
- Timing of the pre-treatment PET measurement(s): aimed for $T_{\text{max}}$ and/or $T_{\text{trough}}$?
- Multiple pre-treatment PET measurements to investigate the time course of the target occupancy?
- Effects of the test drug on cerebral blood flow. PET measurements should be performed at the physiological steady state, i.e., not when cerebral blood flow undergoes (rapid) changes due to the test drug.

Clinical PET occupancy study

Safety data of the test drug should be available prior to the PET study. At least one baseline PET measurement (i.e., when no test drug is administered before PET measurement) and one pretreatment PET measurement (i.e., the test drug is administered before PET measurement) should be performed per subject. Theoretically, the relationship between target occupancy and dose/plasma concentration of the drug can be established from just a single occupancy data point according to the law of mass action, provided the drug only interacts with a single binding site. However, considering the presence of noise in the PET data, it is advisable to have as many points as possible to examine the relationship between dose or plasma concentration of the drug and target occupancy. Ideally, several different doses should be used in order to cover the entire range from low to high occupancy levels. In addition, to account for intersubject variability, it is recommended to scan several subjects with the same dose.

The study design of a clinical PET occupancy study depends on the following factors:

a. Radioligand synthesis at the facility.

b. Radiation dosimetry

- The total number of PET measurements is limited by the radiation absorbed dose received by the subjects. Generic dosimetry tables are available for both $^{18}$F and $^{11}$C labelled brain tracers, for adults indicating effective doses of 4.3 ($^{11}$C) and 28 ($^{18}$F) μSv/MBq, respectively [5], illustrating that more repeat studies can be performed using an $^{11}$C labelled tracer. For novel ligands, as it depends on the kinetics of the radioligands [6, 7], the absorbed dose of individual radioligand should be investigated. The ICRP has published absorbed dose constraints for medical exposure for volunteers in biomedical research, depending on its benefit to society ranging from 0.1 mSv for minor benefit to 10 mSv for moderate benefit, and > 10 mSv only for substantial benefit [8]. Research studies in healthy volunteers can be considered of intermediate to moderate benefit, depending on the type of the study. For each clinical PET occupancy study, the total number of PET measurements per subject together with injected radioactivity per PET measurement should result in a radiation absorbed dose, which is accepted by the local radiation safety committee. When PET/CT is used, additional radiation exposure from CT should be added for the radiation absorbed dose. PET/MRI or digital PET might help to lead to less radiation exposure in the future.

c. Availability of human subjects

- Age, gender, healthy volunteers or patients; in general, dose-occupancy studies are first performed in healthy subjects, but the findings need to be substantiated in a target patient population.
- In those cases in which it is difficult to perform a baseline PET measurement, e.g., in cases of drug naïve patients with schizophrenia, a normal database can be used as a reasonable alternative for the baseline measurements. However, this approach should be considered with caution considering the potential differences between the two groups of subjects.

d. Characteristics of the radionuclide

- The half-life of the radionuclide (e.g., C-11 or F-18) used for labelling, defining the minimum interval
between measurements (at least 5 half-lives) and the maximum number of PET measurements per subject.

- Brain kinetics of the radioligand, defining the minimum duration of a PET measurement, e.g., 60 min for [11C]raclopride (dopamine D2 receptor), which requires a radionuclide with a suitable half-life.

e. Blood sampling and metabolite analysis

- For many PET radioligands (i.e., all radioligands without a valid reference region), arterial input is essential for quantitative analysis of occupancy levels.

  Is arterial sampling feasible?
  Is the amount of blood to be withdrawn acceptable?
  Is equipment for metabolite analysis and measurement of protein binding available?

f. Pharmacokinetics of the test drug

- Safety data, single dose or multiple doses.
- Time to reach the maximum plasma level of the drug.
- Presence of active metabolites
- Timing of pre-treatment PET measurement(s): aimed for T max and/or T trough? Multiple pretreatment PET measurements to investigate the time course of target occupancy.
- Effects of the test drug on cerebral blood flow. PET measurements should be performed at physiological steady state, i.e., not when cerebral blood flow undergoes (rapid) changes due to the test drug.

In some cases, e.g., because of safety issues, only a limited range of doses of the test drug can be investigated in a human occupancy study, precluding a full assessment of the relationship between target occupancy and drug dose. If occupancies are obtained only at high (i.e. >95 %) or low (i.e. <10 %) levels, it might be difficult to assess whether this is due to technical problems in the quantification of the occupancy or due to the non-optimal dose selection of the test drug. If preclinical PET occupancy data are available for a wider range of occupancies, the missing human occupancy data may be extrapolated, provided the animal data can be extrapolated to the human situation. In clinical PET occupancy studies, especially when preclinical PET occupancy data are not available, the doses of the test drugs should ideally be determined using an adaptive design. Figure 2 shows an example of a rather poorly defined dose-occupancy curve, which was obtained using doses of the test drug that had been fixed before the start of the PET study. Such an ill-defined dose-occupancy curve can be avoided by using an adaptive design.

**PET data collection**

As for quantitative brain PET studies, dynamic PET measurements are required for an occupancy study. Depending on the selected (required) quantitative analytical method for the radioligand, arterial blood sampling, metabolite analysis for the parent fraction of radioligand and measurement of protein binding may be needed. After administration of the drug under investigation, changes in brain kinetics of the radioligand may occur due to peripheral blocking and/or changes in metabolite profile and protein binding. When a reference tissue model can be used, it is important to assess whether the proposed reference tissue can still be used as reference tissue after administration of the drug. In case of the pretreatment PET scan, one or more venous blood samples are taken to measure the plasma concentration of the test drug. As the plasma concentration of the test drug is expected not to change too much during a PET measurement, often the plasma concentration just before the start of the PET measurement is used as the actual plasma drug concentration. However, blood samples at the end of the PET scan should also be collected to make sure that the plasma drug concentration has not changed too much and, in some cases, the mean of the plasma concentrations at start and end of a PET scan are used for the pretreatment plasma drug concentration.

**PET data analysis**

*Calculation of outcome measures for radioligand binding*

Calculation of outcome measures for PET occupancy studies is based on established quantitative methods for individual
radioligands. For a full description of the nomenclature of the outcome measures used for quantification, see Innis et al. [4].

A general procedure of PET data analysis is as follows. First, for each individual subject, an MRI scan is acquired. Next, a summed PET image is generated from the dynamic PET scan to enable co-registration of PET and MRI images. After co-registration, the MRI is used to delineate regions of interest (ROIs). Projecting these ROIs on the (co-registered) PET scan then generates corresponding time-activity curves.

If studies are performed using a radioligand for which a region in the brain exists that is devoid of the target being studied (a so called reference region), reference tissue models can be used such as the simplified reference tissue model (SRTM), the Logan non-invasive method, or various multilinear reference tissue models, depending upon which method has been validated for the quantification of the radioligand being used [9–11].

When a radioligand is used for which no reference region exists, the only option is to perform kinetic analysis using a metabolite corrected arterial input function. In general, only \( V_T \) can be obtained as outcome measure (i.e., including a non-specific component), as direct estimates of \( BP_{ND} \) and \( V_S \) tend to be less robust (i.e., with large standard errors).

Although in some cases SUV or SUVr have been used as surrogate outcome measures within the context of an occupancy study [12], in general this approach is questionable, as SUV and to some extent SUVr depend on delivery (plasma curve, perfusion), which may be affected by the drug. As for any simplification, this approach can only be used after full validation against full kinetic analysis.

Automated ROI delineation with or without partial volume correction can be used for analysing PET occupancy data. Parametric occupancy images can be generated as well. However, ROI delineation and partial volume correction should be exactly the same for both baseline and pretreatment PET scans.

**Calculation of the target occupancy**

As mentioned above, in case of radioligands for which a reference region exists, \( BP_{ND} \) is the outcome measure. Using \( BP_{ND} \), occupancy \( Occ \) can be calculated as follows:

\[
Occ (\%) = 100 \times \left( \frac{BP_{ND}^{baseline} - BP_{ND}^{drug}}{BP_{ND}^{baseline}} \right)
\]

where \( BP_{ND}^{baseline} \) is \( BP_{ND} \) under baseline conditions and \( BP_{ND}^{drug} \) that after administration of the test drug.

In case of radioligands for which no reference region exists, \( V_T \) is calculated as outcome measure. However, \( V_T \) consists of a specifically bound part (\( V_S \)) and a nondisplacable part (\( V_{ND} \)).
which means that occupancy is not directly proportional to the change in $V_T$. There are several methods to estimate $V_{ND}$: for example, the method proposed by Lassen et al. [13] in which $V_{ND}$ is derived from the various $V_T$ values obtained in a PET occupancy study. Although this method is easy to apply, it is important to check whether the underlying assumptions of identical occupancy levels and $V_{ND}$ values across the brain are still valid for the study.

For radioligands with irreversible binding to the target, such as $[^{11}C]$-L-deprenyl-D$_2$ (monoamine oxidase type B (MAO-B), $k_3$ or $\lambda k_3$ can be used as outcome measure to be used in Eq. 1 for calculating inhibition ($\lambda = K_1/k_2$) [14, 15].

Estimation of $K_d^{\text{plasma}}$ of the test drug

After occupancy values have been calculated from the PET measurements, they can be plotted against administered dose and/or plasma level of the test drug. Based on the Hill equation [16], the plotted data can be fitted to the following equation,

$$
\text{Occ} \% = \frac{C_p^{\text{drug}}}{(C_p^{\text{drug}} + K_d^{\text{plasma}})} \times \text{Occ}_{\text{max}},
$$

where $\text{Occ}_{\text{max}}$ represents the maximum occupancy and $C_p^{\text{drug}}$ is the plasma concentration of the test drug or, alternatively, the dose administered.

Occ$_{\text{max}}$ might be fixed to 100 % or estimated based on the actual data. $K_d^{\text{plasma}}$ corresponds to the plasma concentration (or dose) at which the target occupancy is 50 %. The equation was originally based on $K_d$, which is the dissociation constant for the local concentration at the target binding. In practice, $K_d^{\text{plasma}}$ is used as a surrogate of $K_d$ based, assuming that the two are correlated.

As it is not guaranteed that the relationship between radioligand and test drug can be described by a Hill equation, pharmacological information on both radioligand and test drug should be considered before applying Eq. 2.

PET occupancy studies as a dose selection tool for clinical trials

The relationship between target occupancy by a drug and its clinical efficacy and/or presence of side effects has been established successfully for a limited number of targets, such as the dopamine D$_2$ receptor and the 5-HT transporter [17–19]. For example, in case of the dopamine D$_2$ receptor, approximately 70 % occupancy is necessary for clinical efficacy, but more than 80 % occupancy is related to the extrapyramidal symptoms (Fig. 3) [17]. For new drug targets, such a relationship should ideally be established in phases 2 and 3 of the drug development program. Based on the relationship between test drug’s dose and the target occupancy, as shown in Fig. 4, several doses of a test drug can be chosen for further clinical trials, e.g., the first dose could correspond with 20 % target occupancy, the second with 50 % and the third with 80 %. If the appropriate dose to show the clinical efficacy is not known beforehand, this procedure will provide the most efficient approach to obtain maximal clinical efficacy together with minimal side effects. In other words, a PET occupancy study is an ideal way to select an appropriate drug dose for further clinical trials. In any case, it provides a means to avoid selecting too high or too low doses. Finally, by performing PET measurements at various times after treatment, the time course of target occupancy can be established, which helps in the selection of the optimal dosing regimen of the test drug (Fig. 5) [20, 21].

Finally, as drug development in pharmaceutical companies is usually performed under tight time constraints, appropriate PET occupancy study protocols based on these guidelines are expected to help to speed up the drug development.

Acknowledgments We would like to thank the members of Dosimetry Committee, Neuroimaging Committee, Radionuclide Therapy Committee, and Radiopharmacy Committee for their helpful comments.

Compliance with ethical standards

Funding None of co-authors had any conflict of interest for this guideline.

Disclosure of potential conflicts of interest None of co-authors had any conflict of interest for this guideline.

Ethical approval This article did not contain any studies with human participants or with animals performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.
2. Lee CM, Farde L. Using positron emission tomography to facilitate CNS drug development. TRENDS Pharmacol Sci. 2006;27:310–6.
3. Hallidin C, Gulyás B, Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des. 2001;7:1907–29.
4. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.
5. ICRP Publication 106. Radiation dose to patients from radiopharmaceuticals. Ann. ICRP 2008, 38: 61–84.
6. Zanotti-Fregonara P, Innis RB. Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2012;39:544–7.
7. Zanotti-Fregonara P, Lammertsma AA, Innis RB. Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013;40:1781–3.

8. ICRP publication 103. The 2007 recommendations of the international commission on radiological protection. Ann ICRP. 2007; 37: 116–117.

9. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834–40.

10. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8.

11. Ichise M, Liow JS, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096–112.

12. Terry GE, Liow JS, Zoghbi SS, Hirvonen J, Farris AG, Lerner A, et al. Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage. 2009;48:362–70.

13. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, et al. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: Application of the steady-state principle. J Cereb Blood Flow Metab. 1995;15:152–65.

14. Bench CJ, Price GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, et al. Eur J Clin Pharmacol. 1991;40:169–73.

15. Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med. 1995;36:1255–62.

16. Hill AV. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol. 1910;40:iv–vii.

17. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538–44.

18. Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, et al. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and [11C]-raclopride. Psychopharmacol (Berl). 1993;112(2–3):308–14.

19. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826–35.

20. Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M, et al. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacol (Berl). 1996;124:141–7.

21. Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacol (Berl). 2006;185:395–9.